Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06148480
Other study ID # IRB 2020-3331
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 17, 2020
Est. completion date December 31, 2026

Study information

Verified date November 2023
Source Ann & Robert H Lurie Children's Hospital of Chicago
Contact Mehreen Arshad
Phone 3122274668
Email marshad@luriechildrens.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

We aim to conduct a prospective surveillance study of mothers and their infants born vaginally or by scheduled C-section and who are admitted to Northwestern Medicine Prentice Women's Hospital to determine the prevalence of ESBL-E carriage in healthy post-partum women and the transmission rate of these strains to their infants. Using whole genome sequencing and a comparative genomics approach we will determine the relatedness of strains among mother-infant dyads as well as identify genetic regions common to transmitted strains. We hypothesize that; 1) given the diverse population of Chicago there will be a significant rate of gut colonization with ESBL-E among mothers admitted to Prentice, 2) ESBL-E strains isolated from neonates will be identical to those from their mothers and 3) genetic determinants of transmission are conserved across ESBL E. coli strains that are perinatally transmitted. These hypotheses will be tested using the following Aims: Aim 1: Determine the prevalence of ESBL-E gut colonization and rate of perinatal transmission among mother-infant dyads Aim 2: Identify genetic determinants of transmission common to ESBL E. coli that are perinatally transmitted. Our long-term goal is to understand the unique features of persistent gut and vaginal ESBL-E colonizers and identify genetic and molecular elements that could be attractive therapeutic targets to decrease the burden of ESBL-E colonization and perinatal transmission.


Description:

The rapid rise of multi-drug resistant Enterobacteriaceae (MDR-E) is severely threatening the way we treat common infectious diseases. A particularly vulnerable population are neonates where a delay in the treatment of MDR-E sepsis can be fatal. Additionally, highly drug resistant bacteria such as the pandemic E. coli ST131 strain are persistent gut and vaginal colonizers (1). In animal models of gut colonization, these strains out-compete drug-sensitive, commensal Escherichia coli. Early life exposure to MDR-E could, therefore, have long-lasting effects on the developing microbiome and overall child health (2). Among extra-intestinal pathogenic Enterobacteriaceae, resistance against a number of antibiotics, especially the beta-lactams, has rapidly risen in the last decade. Since the gut is a major reservoir of these pathogens even in otherwise healthy individuals it is likely that there is a concomitant increase in gut colonization with extended spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) among the general population (3, 4). Even in regions with a low prevalence of community acquired ESBL-E infections, perinatal transmission occurs in 35% of infants born to mothers colonized with these strains (5). We and others have recently shown that healthy infants in South Asia, a region with a high use of antibiotics per capita, are carriers of ESBL-E (6). In vitro studies in our lab suggest that ESBL E. coli isolated from these infants have a higher growth potential than commensal E. coli. Using a murine model of perinatal transmission of E. coli, we have shown that some of the ESBL E. coli strains adept in human infant gut colonization can also readily colonize pregnant dams and be perinatally transmitted. The burden of ESBL-E colonization among pregnant women and their neonates in the US and the genetic determinants of perinatal transmission are unknown. We aim to conduct a prospective surveillance study of mothers and their infants born vaginally and who are admitted to Northwestern Medicine Prentice Women's Hospital to determine the prevalence of ESBL-E carriage in healthy post-partum women and the transmission rate of these strains to their infants. Using whole genome sequencing and a comparative genomics approach we will determine the relatedness of strains among mother-infant dyads as well as identify genetic regions common to transmitted strains. We hypothesize that; 1) given the diverse population of Chicago there will be a significant rate of gut colonization with ESBL-E among mothers admitted to Prentice, 2) ESBL-E strains isolated from neonates will be identical to those from their mothers and 3) genetic determinants of transmission are conserved across ESBL E. coli strains that are perinatally transmitted. These hypotheses will be tested using the following Aims: Aim 1: Determine the prevalence of ESBL-E gut colonization and rate of perinatal transmission among mother-infant dyads Aim 2: Identify genetic determinants of transmission common to ESBL E. coli that are perinatally transmitted. Our long-term goal is to understand the unique features of persistent gut and vaginal ESBL-E colonizers and identify genetic and molecular elements that could be attractive therapeutic targets to decrease the burden of ESBL-E colonization and perinatal transmission.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date December 31, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria: Women that are admitted to Northwestern Medicine Women's Hospital that have delivered an infant vaginally or have had a scheduled C-section without preceding labor. Infants that are born vaginally who are healthy and do not require transfer to the NICU for any reason. Exclusion Criteria: Temperature >38 Celsius in labor, caesarean section after labor, rupture of membranes or done emergently, antibiotic use in last trimester including for GBS+, delivery at <35 weeks, immunocompromised host including being HIV+, infant requiring transfer to NICU for any reason and infants who are transferred to the NICU.

Study Design


Locations

Country Name City State
United States Prentice Women's Hospital Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Ann & Robert H Lurie Children's Hospital of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary ESBL-E Prevalence Determine the proportion of women in the post-partum period that are colonized with ESBL-E Baseline
Primary Transmission Among Mother-Infant Dyads Determine the proportion of neonates that acquire ESBL-E strains perinatally Baseline
Primary Persistence of ESBL-E Colonization For determine colonization of ESBL-E organisms in neonates 7 days after birth. 7 days from baseline
Secondary Genetic Determinants of ESBL-E Identifying specific genes that are important for successful perinatal transmission of ESBL-E Baseline
See also
  Status Clinical Trial Phase
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Completed NCT02909946 - Pathway From Functional Disability to Antimicrobial Resistance in Nursing Home Residents N/A
Recruiting NCT04335383 - Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Recruiting NCT04181112 - Fecal Transplant for MDRO Decolonization N/A
Completed NCT05048693 - Use of New Antibiotics in Sweden
Completed NCT05897801 - Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO
Completed NCT04212130 - Can Environmental Cleanliness be Assessed by BCA (Bicinchoninic Acid) Method N/A
Completed NCT05100407 - Factors Impacting the Prevalence of MDR Bacteria
Completed NCT05549427 - Ventilator Associated Pneumonia by Multi-Drug Resistant Organism
Not yet recruiting NCT06370299 - Screening of Multidrug Resistant Bacteria, and the Clinical Implication for the Patient
Recruiting NCT04995133 - Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs. Phase 4
Recruiting NCT03921645 - Use of Aaerosol Combined With Intravenous Antibiotics for the Treatment of Multidrug Resistant GNB Pneumonia N/A
Completed NCT06199141 - Multi-drug Resistant Gram-negative Bacteria and Veno-venous Extracorporeal Membrane Oxygenation (ECMO)
Recruiting NCT04759001 - FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae Phase 1/Phase 2
Not yet recruiting NCT05791396 - FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae Phase 1/Phase 2
Terminated NCT02906774 - Fecal Transplant for MDR Pathogen Decolonization
Recruiting NCT06036628 - Resistant Bacteria in Children in France